Re­cur­sion and Bay­er to wind down fi­bro­sis R&D pact af­ter three years, re­fo­cus­ing on can­cer

Re­cur­sion Phar­ma­ceu­ti­cals and Bay­er re­worked a re­search pact to fo­cus on on­col­o­gy in­stead of fi­bro­sis as the Ger­man drug­mak­ing gi­ant homes in on can­cer un­der …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER